Parkinson's Disease: World Drug Industry and Market 2014-2024

LONDON, February 6, 2014 /PRNewswire/ --

Treating Parkinson's - how you find business trends, R&D, and revenue forecasts

See the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research and development. You unlock that CNS medical industry. And you assess its results, trends, technologies, therapies, and opportunities.

Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data, then, finding commercial prospects. And you hear about gains for companies, doctors, and patients, also benefiting your influence.

So read on to investigate those medicines and see what their future could be worth.

Sales predictions to 2024 and other analyses show you commercial prospects

Besides forecasting revenues to 2024, our study gives you recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). Also you get 68 tables, 47 charts, and interviews with two companies.

There you discover the most lucrative opportunities for treating that central nervous system (CNS) disorder. You find where the money lies, exploring existing and potential sales.

Knowledge to help your work on that degenerative disorder

Ever found business data hard to find? Instead see how our report helps your research, analyses, and decisions for treatment of Parkinson's disease (PD). Save time too, and stay ahead. Also benefit your authority through better understanding the present and future.

Avoid missing out. And the following sections explain what you get in that new investigation.

Forecasting of that world market and its segments - you explore possibilities

What're the secrets of that industry's progress? Where lies potential in alleviating symptoms and treating PD? Discover in our report overall world revenue to 2024 for those central nervous system (CNS) medicines.

Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:
• Dopaminergic agents
• Dopamine receptor agonists
• COMT inhibitors
• MAO inhibitors
• Treatments with other modes of action (grouped).

There you assess outlooks for sales growth, seeing where you can gain.

Like to know what happens next? You explore competition and rising sales for products, including biological drugs (biologics). You get feel for that sector and its potential.

So discover the sales possibilities there. See, too, how patients benefit. And you find top products' potentials.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Predictions of revenues for leading Parkinson's drugs

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for three leading products:
• Comtan and Stalevo
• Azilect
• Neupro.

There you find products and years with highest predicted revenues and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. Discover where you could profit.

Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for selling products treating Parkinson's disease will improve from 2014 to 2024. See where and how, finding commercial potentials of therapeutic agents for that neurodegenerative disorder.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for that specialist medicine.

Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers tackling that neurological disease.

Also, what events change that market? Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling PD medicines

Our report shows you issues and events affecting that biomedical and pharma segment from 2014, including these:
• R&D for Parkinson's (idiopathic or primary parkinsonism, hypokinetic rigid syndrome/HRS, or paralysis agitans), including stem cells and gene therapy
• Levodopa therapy, its reformulations, and patient expiry - rising competition
• Demographic trends worldwide affecting treatment needs and demand for PD drugs
• Economic changes stimulating sales of those medical agents
• Neuroprotective medicines (neuroprotection) giving hope.

So you explore political, economic, social, and technological questions for treating Parkinson's, investigating outlooks for commerce. See too how R&D can let companies benefit patients. Discover what the future holds.

You find, then, what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Companies and 2018 market value - find prospects for success in PD medicines

What happens next? Our new study predicts the world market for Parkinson's-treating drugs will reach $3461m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.

And there you examine activities of many organisations, including these firms:
• Orion Pharmaceuticals
• Novartis
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Teva Pharmaceutical Industries.

R&D for treating PD holds advantages, and from 2014 there will arise opportunity. From this decade, patients, payers, and producing companies will benefit.

And you discover how that market can perform, staying ahead in data.

Ways Parkinson's Disease: World Drug Industry and Market 2014-2024  helps you

In particular, our investigation gives you this knowledge:
• Revenues there to 2024 at world level, for 5 submarkets, and 3 top products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the business possibilities.

With our data you're less likely to fall behind in knowledge or miss opportunity for treating that nervous system disease. Being free to choose, you find how you could save time and effort with our study, helping your planning, decisions, and influence.

Trying our report now lets you discover Parkinson's drug opportunities and forecasts

Our new report is for everyone analysing medications for neurodegenerative disorders. There you find sales predictions and discussions. Avoid missing out - please order now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1195/Parkinson%27s-Disease-World-Drug-Industry-and-Market-2014-2024

Companies Listed in this Report:

Abbott Laboratories
AbbVie Pharmaceuticals
Acadia Pharmaceuticals
Adamas Pharmaceuticals
Addex Therapeutics
Amarantus BioSciences
American Academy of Neurology
Amgen
Amicus Therapeutics
Amylin Pharmaceuticals
Ark Therapeutics
Assogenerici
AstraZeneca
Avanir Pharmaceuticals
Axxonis Pharma
BIAL - Portela
Biogen Idec
Bioprojet Pharma
BioSante Pharmaceuticals
Biotie Therapies
Biovail
Boehringer Ingelheim
Cardiovascular and Renal Drug Advisory Committee
Ceregene
Chelsea Therapeutics
Civitas Therapeutics
Columbia University
Dainippon Sumitomo Pharma
Depomed
DiaGenic
Domain Therapeutics
Dr. Reddy's Laboratories
Duke University, Duke Medical Center
Durin Technologies
Eisai
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
Genzyme
GlaxoSmithKline (GSK)
Impax Laboratories
Intec Pharma
International Stem Cell Corporation (ISCO)
Ipsen
Juvantia Pharma
Kyowa Hakko Kirin
Lundbeck
Meiji Seika
Merck & Co.
Merck Serono
Ministry of Health, Labour and Wealth (MHLW)
Mundipharma Research
Mylan
Napp Pharmaceuticals
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Neurological Disorders and Stroke (NINDS, US)
National Institutes of Health (NIH, US)
National Parkinson Foundation
Neuren Pharmaceuticals
Neuroderm
NeuroGeneration
NeuroHealing Pharmaceuticals
Neurologix
New Jersey School of Osteopathic Medicine (UMDNJ-SOM)
Newron Pharmaceuticals
Novartis
NuroPro
Ono Pharmaceuticals
Orient Pharma
Orion
Otsuka Pharmaceuticals
Oxford BioMedica
Par Pharmaceuticals
Parkinson's UK
Pfizer
Pharmaceutical Research and Manufacturers Association (PhRMA)
Phytopharm
Power3 Medical Products
Prothena Corporation
Roche
Roxane Laboratories
Sanofi
Santhera
Schering Plough
Sheffield Institute for Translational Neuroscience (SITraN)
SK Biosciences
Skyepharma
Sun Pharmaceuticals
Technion-Israel Institute of Technology
Teva Pharmaceutical Industries
The Michael J. Fox Foundation
The Parkinson Study Group
Titan Pharmaceuticals
UCB
uniQure
University College London (UCL)
Valeant
Varinel
Vectura Group
Vernalis
Watson Pharmaceuticals
Wockhardt
XenoPort
Yale University
Zambon Group

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com